PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
Article in Future Oncology (July 2024)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
CTHRC1 is a prognostic biomarker correlated with immune infiltration in head and neck squamous cell carcinoma
Article in BMC Oral Health (June 2024)
The expression of immune co-stimulators as a prognostic predictor of head and neck squamous cell carcinomas and oral squamous cell carcinomas
Article in Journal of Dental Sciences (May 2024)